Perspective Therapeutics Inc. share price logo

Perspective Therapeutics Inc. Share Price

NYSE: CATX

Small Cap

$3.56

+0.08

(+2.30%)

as on

Perspective Therapeutics Inc. Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $3.45
    $3.74
    downward going graph

    3.09%

    Downside

    5.06%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.6
    $15.28
    downward going graph

    55.06%

    Downside

    329.07%

    Upside

    downward going graph

Perspective Therapeutics Inc. share price movements today

Previous Close
$3.48
Open
$3.50
Volume
1.7M
Day's Low - High
$3.45 - $3.74
52 Week Low - High
$1.6 - $15.28

Perspective Therapeutics Inc. Historical Returns

1 Month Return
-3.6 %
3 Month Return
+ 9.78 %
1 Year Return
-76.95 %
3 Year Return
0 %
5 Year Return
0 %

Perspective Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Perspective Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$258.4M

EPS (TTM)

-1.1742

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-82.6M

Revenue (TTM)

1.2M

Profit Margin

0.00%

Return On Equity TTM

0.00%

Perspective Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Perspective Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$258.4MNANA0.00%
BUY$152.2B150.39%61.1413.55%
BUY$146.6B82.11%50.7712.25%
BUY$232.8B25.47%16.7832.43%
BUY$120.6B-12.59%25.9813.63%

Stock Returns calculator for Perspective Therapeutics Inc. Stock including INR - Dollar returns

The Perspective Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Perspective Therapeutics Inc. investment value today

Current value as on today

₹28,562

Returns

₹71,438

(-71.44%)

Returns from Perspective Therapeutics Inc. Stock

₹76,424 (-76.42%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Perspective Therapeutics Inc. Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Perspective Therapeutics Inc.. Average target price of $13.96

Perspective Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Perspective Therapeutics Inc..

What analysts predicted

74.5%UPSIDE

Target Price

$13.96

Current Price

$3.56

Analyzed by

8 Analysts

Target

$13.96

Perspective Therapeutics Inc. target price $13.96, a slight upside of 74.5% compared to current price of $3.56. According to 8 analysts rating.

Perspective Therapeutics Inc. Stock's Interest Amongst Investors

Search interest for Perspective Therapeutics Inc. Stock has decreased by -79% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-79% versus previous 30 day period

Perspective Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
1
1
1
0
-
-
-
-
0
0
Gross Profit
0
0
0
0
-
-
-
-
0
0
Operating Income
-11
-11
-10
-7
-13
-14
-18
-44
-21
-20
EBITDA
-10
-11
-9
-8
-11
-10
-14
-43
-17
-41
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-11
-10
-8
-11
-11
-15
-42
-18
-42
Income Tax Expense
-10
0
0
7
-
0
-
-2
-
-2
Net Income
0
-11
-10
-24
-12
-11
-15
-40
-18
-40
Net Profit Margin
-20.27%
-740.40%
-542.48%
-7321.96%
0.00%
0.00%
0.00%
0.00%
-5314.91%
-17166.24%

Perspective Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Jun 2020
Dec 2020
Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Dec 2024
Total Revenue
9
9
10
10
10
10
7
7
1
-
Gross Profit
5
5
5
5
4
4
1
1
1
-
Operating Income
-3
-3
-3
-3
-7
-7
-15
-15
-40
10
EBITDA
-3
-3
-3
-3
-
-7
-14
-14
-39
10
Interest Expense
-
0
-
0
-
0
0
-
0
0
Depreciation
0
0
0
0
0
0
-
-
0
2
Income Before Tax
-3
-3
-3
-3
-7
-7
-14
-14
-40
-81
Income Tax Expense
0
0
0
0
-
0
0
-
-2
-2
Net Income
-3
-3
-3
-3
-7
-7
-14
-14
-46
-79
Net Profit Margin
-33.77%
-33.77%
-31.71%
-31.71%
-67.36%
-66.26%
-206.50%
-206.50%
-3243.24%
0.00%

Perspective Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-11
-10
-24
-12
-11
-15
-40
-18
6
Operating Cash Flow
-8
-10
-9
13
-8
3
-26
-21
-13
Investing Cash Flow
0
0
0
-47
-3
-29
-138
-5
0
Financing Cash Flow
0
0
0
166
122
0
0
9
9
Change in Cash
-8
-10
-8
142
109
-25
-164
-17
19

Perspective Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Jun 2020
Dec 2020
Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Dec 2024
Net Income
-3
-3
-3
-7
-7
-14
-14
-46
-79
Operating Cash Flow
-3
-2
-2
-7
-7
-12
-12
-36
-18
Investing Cash Flow
0
0
0
-
0
-57
-
24
-218
Financing Cash Flow
0
64
64
0
0
0
0
0
289
Change in Cash
-2
61
61
-7
-7
0
0
-46
52

Insights on Perspective Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Boston Scientific Corp. has given 23.3% return, outperforming this stock by 100.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, CATX stock has moved down by -77.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -18.17M → -40.16M (in $), with an average decrease of 121.0% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 342.0K → 234.0K (in $), with an average decrease of 31.6% per quarter

About Perspective Therapeutics Inc.

the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct
OrganisationPerspective Therapeutics Inc.
Headquarters2401 Elliott Avenue, Seattle, WA, United States, 98121
CEOMr. Johan M. Spoor
E-voting on sharesClick here to vote

Key Management of Perspective Therapeutics Inc.

Name

Title

Mr. Jonathan R. Hunt

Chief Accounting Officer

Mr. Andrew Bright

Executive Vice President of Brachytherapy

Mr. Amos Hedt BA, PGradDip

Chief Business Strategy Officer

Mr. Shane Cobb

Executive Vice President of Operations

Dr. Michael K. Schultz Ph.D.

Chief Science Officer

Ms. Annie J. Cheng

Vice President of Investor Relations

Mr. Chris Nenno

General Counsel & Corporate Secretary

Mr. Johan M. Spoor

CEO & Director

Dr. Markus Puhlmann M.B.A., M.D.

Chief Medical Officer

Mr. Joel David Sendek

Chief Financial Officer

FAQs

What is Perspective Therapeutics Inc. share price today?

Perspective Therapeutics Inc. share price today is $3.56 as on at the close of the market. Perspective Therapeutics Inc. share today touched a day high of $3.74 and a low of $3.45.

What is the 52 week high and 52 week low for Perspective Therapeutics Inc. share?

Perspective Therapeutics Inc. share touched a 52 week high of $15.28 on and a 52 week low of $1.6 on . Perspective Therapeutics Inc. stock price today i.e. is closed at $3.56,which is 76.69% down from its 52 week high and 122.50% up from its 52 week low.

What is Perspective Therapeutics Inc.'s market capitalisation today?

Perspective Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Perspective Therapeutics Inc. Stock (CATX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Perspective Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Perspective Therapeutics Inc. Shares that will get you 0.4213 shares as per Perspective Therapeutics Inc. share price of $3.56 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Perspective Therapeutics Inc. Stock (CATX) from India?

Indian investors can start investing in Perspective Therapeutics Inc. (CATX) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Perspective Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Perspective Therapeutics Inc. share’s latest price of $3.56 as on September 16, 2025 at 1:29 am IST, you will get 2.8090 shares of Perspective Therapeutics Inc.. Learn more about fractional shares .